EP1583836A4 - PROCEDE D'INTRODUCTION DE siRNA DANS DES ADIPOCYTES - Google Patents

PROCEDE D'INTRODUCTION DE siRNA DANS DES ADIPOCYTES

Info

Publication number
EP1583836A4
EP1583836A4 EP03813009A EP03813009A EP1583836A4 EP 1583836 A4 EP1583836 A4 EP 1583836A4 EP 03813009 A EP03813009 A EP 03813009A EP 03813009 A EP03813009 A EP 03813009A EP 1583836 A4 EP1583836 A4 EP 1583836A4
Authority
EP
European Patent Office
Prior art keywords
adipocytes
methods
introducing sirna
identifying
introducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03813009A
Other languages
German (de)
English (en)
Other versions
EP1583836A2 (fr
Inventor
Michael P Czech
Qionglin Zhou
Zhen Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts UMass
Original Assignee
University of Massachusetts UMass
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts UMass filed Critical University of Massachusetts UMass
Publication of EP1583836A2 publication Critical patent/EP1583836A2/fr
Publication of EP1583836A4 publication Critical patent/EP1583836A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Il s'avère, en général, difficile d'introduire des séquences d'acide nucléique dans des adipocytes. Selon cette invention, les procédés d'introduction des acides nucléiques tels que les siRNA dans des adipocytes comprennent l'introduction de séquences ciblant Akt1, Akt2 et Myo1c. L'invention porte également sur des procédés d'identification de gènes impliqués dans le transport du glucose et sur des procédés d'identification de modulateurs de la réponse insulinique. L'invention porte, en outre, sur des méthodes thérapeutiques.
EP03813009A 2002-12-11 2003-12-11 PROCEDE D'INTRODUCTION DE siRNA DANS DES ADIPOCYTES Withdrawn EP1583836A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43242702P 2002-12-11 2002-12-11
US432427P 2002-12-11
PCT/US2003/039774 WO2004053103A2 (fr) 2002-12-11 2003-12-11 Procede d'introduction de sirna dans des adipocytes

Publications (2)

Publication Number Publication Date
EP1583836A2 EP1583836A2 (fr) 2005-10-12
EP1583836A4 true EP1583836A4 (fr) 2006-12-27

Family

ID=32507923

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03813009A Withdrawn EP1583836A4 (fr) 2002-12-11 2003-12-11 PROCEDE D'INTRODUCTION DE siRNA DANS DES ADIPOCYTES

Country Status (6)

Country Link
US (1) US20050014264A1 (fr)
EP (1) EP1583836A4 (fr)
JP (1) JP2006509504A (fr)
AU (1) AU2003297062A1 (fr)
CA (1) CA2509494A1 (fr)
WO (1) WO2004053103A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050053565A1 (en) * 2003-09-09 2005-03-10 Florian Lang Modulation of hair growth via SGK3
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US8007814B2 (en) 2004-06-16 2011-08-30 University Of Massachusetts Therapy for lysosomal enzyme deficiencies
US7654956B2 (en) * 2004-07-13 2010-02-02 Dexcom, Inc. Transcutaneous analyte sensor
EP1817583A4 (fr) * 2004-12-02 2009-06-03 Univ Massachusetts Gènes et polypeptides associés au transport du glucose et procédés d'utilisation de ceux-ci
WO2007016189A2 (fr) * 2005-07-28 2007-02-08 University Of Massachusetts Genes lies au transport du glucose, polypeptides lies au transport du glucose, et leurs methodes d'utilisation
GB0520063D0 (en) * 2005-10-03 2005-11-09 Novartis Forschungsstiftung Methods for regulating metabolism and diagnosing disease
WO2008109352A2 (fr) * 2007-03-02 2008-09-12 Mdrna, Inc. Composés d'acide nucléique permettant d'inhiber l'expression de gène akt et utilisations de ceux-ci
US8389485B2 (en) 2007-10-29 2013-03-05 University Of Massachusetts Encapsulated nanoparticles for nucleic acid delivery
WO2013017656A1 (fr) * 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonistes de ribonucléases pour traiter l'obésité
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
EP4124658A3 (fr) 2017-10-16 2023-04-19 Voyager Therapeutics, Inc. Traitement de la sclérose latérale amyotrophique (sla)
WO2019079242A1 (fr) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. Traitement de la sclérose latérale amyotrophique (sla)
EP3793616A1 (fr) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions et procédés pour l'administration de vaa
AU2019299861A1 (en) 2018-07-02 2021-01-14 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
US20210371470A1 (en) 2018-10-12 2021-12-02 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
WO2021247995A2 (fr) 2020-06-04 2021-12-09 Voyager Therapeutics, Inc. Compositions et méthodes de traitement de la douleur neuropathique

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032619A1 (fr) * 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
WO1999054465A2 (fr) * 1998-04-20 1999-10-28 Warner-Lambert Company Gene codant pour une proteine interagissant avec une syntaxine
WO2000031291A1 (fr) * 1998-11-19 2000-06-02 Pharmacia Ab Procede de selection de substances qui sont des activateurs, des inhibiteurs ou des liants de la pkb au moyen d'un substrat peptidique et utilisation de ce substrat peptidique
WO2001093669A2 (fr) * 2000-06-08 2001-12-13 Devgen Nv Criblage de composes associes a une insuffisance en insuline ou a une resistance a l'insuline
WO2002033046A2 (fr) * 2000-10-20 2002-04-25 University Of Massachusetts Genes relatifs au transport de glucose
US20020162126A1 (en) * 2000-03-16 2002-10-31 David Beach Methods and compositions for RNA interference

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767077A (en) * 1988-05-27 1998-06-16 Applied Research Systems Ars Holding N.V. Human Fc-γ receptor III
US5744327A (en) * 1990-02-20 1998-04-28 Board Of Regents, The University Of Texas System Methods for producing insulin in response to non-glucose secretagogues
US5459058A (en) * 1991-03-28 1995-10-17 Benjamin Rich Cell culture system
TW289731B (fr) * 1992-07-09 1996-11-01 Akzo Nv
US5565321A (en) * 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
US5834266A (en) * 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5804380A (en) * 1993-11-12 1998-09-08 Geron Corporation Telomerase activity assays
ATE407208T1 (de) * 1994-09-05 2008-09-15 Amrad Operations Pty Ltd Hemopoietin-rezeptor
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
AU6407696A (en) * 1995-07-07 1997-02-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of identifying inhibitors of the jak-stat signal transduction pathway
US6171779B1 (en) * 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
HRP980443A2 (en) * 1997-08-18 1999-10-31 Carl P. Decicco Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
US6365369B1 (en) * 1998-04-01 2002-04-02 Human Genome Sciences, Inc. Prostate specific secreted protein
US20030228597A1 (en) * 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
AR029876A1 (es) * 1998-05-11 2003-07-23 Takeda Pharmaceutical Compuesto de acido oxiiminoalcanoilo, composicion farmaceutica y agente para controlar receptores relacionados con retinoide que lo comprenden y su uso
GB9825953D0 (en) * 1998-11-26 1999-01-20 Medical Res Council Protein fragments for use in protein targeting
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
DE19906564C2 (de) * 1999-02-17 2001-01-25 Peschges Klaus Juergen Verfahren zur Herstellung von dreidimensionalen Gegenständen mittels Stereolithographie
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US6921665B2 (en) * 2000-11-27 2005-07-26 Roslin Institute (Edinburgh) Selective antibody targeting of undifferentiated stem cells
US6642041B2 (en) * 2001-02-05 2003-11-04 Bristol-Meyers Squibb Company Polynucleotides encoding a novel metalloprotease, MP-1
EP1386004A4 (fr) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc Modulation de l'expression genique associee a la proliferation inflammatoire et a la croissance de neurites, par des procedes faisant intervenir l'acide nucleique
WO2002085285A2 (fr) * 2001-04-18 2002-10-31 Wyeth Methodes et compositions permettant de reguler la formation osseuse et cartilagineuse
US7034134B2 (en) * 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
EP1405636A4 (fr) * 2001-06-26 2009-04-15 Takeda Pharmaceutical Regulateur de la fonction du recepteur relatif aux retinoides
AU2002356522A1 (en) * 2001-09-04 2003-04-07 Bristol-Myers Squibb Company Polynucleotide encoding adapter protein, pmn29

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032619A1 (fr) * 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Inhibition genetique par de l'arn double brin
WO1999054465A2 (fr) * 1998-04-20 1999-10-28 Warner-Lambert Company Gene codant pour une proteine interagissant avec une syntaxine
WO2000031291A1 (fr) * 1998-11-19 2000-06-02 Pharmacia Ab Procede de selection de substances qui sont des activateurs, des inhibiteurs ou des liants de la pkb au moyen d'un substrat peptidique et utilisation de ce substrat peptidique
US20020162126A1 (en) * 2000-03-16 2002-10-31 David Beach Methods and compositions for RNA interference
WO2001093669A2 (fr) * 2000-06-08 2001-12-13 Devgen Nv Criblage de composes associes a une insuffisance en insuline ou a une resistance a l'insuline
WO2002033046A2 (fr) * 2000-10-20 2002-04-25 University Of Massachusetts Genes relatifs au transport de glucose

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BOSE A ET AL: "G(alpha)11 signaling through ARF6 regulates F-actin mobilization and GLUT4 glucose transporter translocation to the plasma membrane.", MOLECULAR AND CELLULAR BIOLOGY. AUG 2001, vol. 21, no. 15, August 2001 (2001-08-01), pages 5262 - 5275, XP002387794, ISSN: 0270-7306 *
BOSE AVIRUP ET AL: "Glucose transporter recycling in response to insulin is facilitated by myosin Myo1c.", NATURE. 2002 DEC 19-26, vol. 420, no. 6917, 19 December 2002 (2002-12-19), pages 821 - 824, XP002387796, ISSN: 0028-0836 *
CROSS D A E ET AL: "INHIBITION OF GLYCOGEN SYNTHASE KINASE-3 BY INSULIN MEDIATED BY PROTEIN KINASE B", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 378, no. 6559, 21 December 1995 (1995-12-21), pages 785 - 789, XP002025954, ISSN: 0028-0836 *
CZAUDERNA F ET AL: "Functional stidies of the PI(3)Kinase Signaling Pathway Employing Synthetic and Expressed siRNA", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 31, no. 2, January 2003 (2003-01-01), pages 670 - 672, XP002992229, ISSN: 0305-1048 *
ELBASHIR S M ET AL: "Analysis of gene function in somatic mammalian cells using small interfering RNAs", METHODS : A COMPANION TO METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC., NEW YORK, NY, US, vol. 26, no. 2, February 2002 (2002-02-01), pages 199 - 213, XP002251055, ISSN: 1046-2023 *
JIANG ZHEN Y ET AL: "Insulin signaling through Akt/protein kinase B analyzed by small interfering RNA-mediated gene silencing.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 24 JUN 2003, vol. 100, no. 13, 24 June 2003 (2003-06-24), pages 7569 - 7574, XP002387795, ISSN: 0027-8424 *
KUNIHIKO IZUISHI ET AL: "Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, 1 November 2000 (2000-11-01), pages 6201 - 6207, XP002974604, ISSN: 0008-5472 *
MIN ET AL: "Synip: A Novel Insulin-Regulated Syntaxin 4-Binding Protein Mediating GLUT4 Translocation in Adipocytes", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 3, no. 6, June 1999 (1999-06-01), pages 751 - 760, XP002124922, ISSN: 1097-2765 *
PARADIS S ET AL: "CAENORHABDITIS ELEGANS AKT/PKB TRANSDUCES INSULIN RECEPTOR-LIKE SIGNALS FROM AGE-1 PI3 KINASE TO THE DAF-16 TRANSCRIPTION FACTOR", GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, PLAINVIEW, NY, US, vol. 12, 1998, pages 2488 - 2498, XP002922386, ISSN: 0890-9369 *
SIEGMUND D ET AL: "SELECTIVE INHIBITION OF FLICE-LIKE INHIBITORY PROTEIN (FLIP) EXPRESSION WITH SMALL INTERFERING RNA OLIGONUCLEOTIDES (SIRNAS) IS SUFFICIENT TO SENSITIZE TUMOR CELLS FOR TRAIL-INDUCED APOPTOSIS", MOLECULAR MEDICINE, BLACKWELL SCIENCE, CAMBRIDGE, MA, US, vol. 8, no. 11, November 2002 (2002-11-01), pages 725 - 732, XP009005569, ISSN: 1076-1551 *
TUSCHL THOMAS ET AL: "Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy.", MOLECULAR INTERVENTIONS. JUN 2002, vol. 2, no. 3, June 2002 (2002-06-01), pages 158 - 167, XP002294002, ISSN: 1534-0384 *

Also Published As

Publication number Publication date
EP1583836A2 (fr) 2005-10-12
WO2004053103A3 (fr) 2005-04-21
JP2006509504A (ja) 2006-03-23
CA2509494A1 (fr) 2004-06-24
WO2004053103A2 (fr) 2004-06-24
US20050014264A1 (en) 2005-01-20
AU2003297062A1 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
WO2004053103A3 (fr) Procede d'introduction de sirna dans des adipocytes
WO2004033620A3 (fr) Procedes et compositions permettant l'utilisation therapeutique de l'interference arn
WO2003072711A3 (fr) Procede d'utilisation d'oligonucleotides modifies pour l'administration hepatique
WO2005089735A3 (fr) Compositions et procédés servant à traiter un cancer des poumons
WO2000052155A3 (fr) Recombinaison d'acides nucleiques d'insertion modifies
WO2004011647A8 (fr) Petites molécules modifiées d'arn d'interférence et leurs procédés d'utilisation
AU2001234857A1 (en) Electroporation and electrophoresis system and method for achieving molecular penetration into cells in vivo
WO2003046173A1 (fr) Systeme d'expression d'arn si et procede de production de cellules d'inactivation de genes fonctionnelles et analogues au moyen de ce systeme
WO2005069987A3 (fr) Amplification de l'expression d'arn interferent (arni) et effets associes
WO2006071776A3 (fr) Amplification d'arn fondee sur la ligature
WO2011038160A3 (fr) Compositions et procédés pour réduire au silence des gènes exprimés dans le cancer
WO2008092081A8 (fr) ADMINISTRATION CIBLÉE D'ARNsi
AU2003221584A1 (en) Methods for delivering nucleic acid molecules into cells and assessment thereof
WO2003046186A8 (fr) Systeme d'expression d'arnsi et procede de production de cellule knockdown a gene fonctionnel ou analogue utilisant ce systeme
WO2006045591A3 (fr) Procede et produits de synthese permettant d'administrer un arn en double brin a des organismes de parasites
EP1667728A4 (fr) Delivrance intravasculaire d'un acide nucleique non viral
WO2005090572A3 (fr) Compositions et procédés servant à traiter un cancer du pancréas
WO2008070477A3 (fr) Conjugués d'arn à interférence courte polymères
WO2005054439A3 (fr) Manipulation genetique hereditaire via l'arnsi dans des plantes
WO2004090094A3 (fr) L-carnitine deshydrogenases, leurs derives et procede de production de (s)-alcanols substitues
WO2004076623A3 (fr) Compositions et methodes permettant d'inhiber la croissance cellulaire
WO2004013313A3 (fr) Acides nucleiques antisens
WO2005014607A3 (fr) Modulation antisens de l'expression de la stearoyl-coa desaturase
GB2350060A (en) Nucleic acid delivery
WO2004101749A3 (fr) Procedes pour amplifier des sequences d'acides nucleiques par ligature decalee

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050707

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1083108

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20061128

17Q First examination report despatched

Effective date: 20070327

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090701

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1083108

Country of ref document: HK